Lupin, DKSH enter pact to commercials Alvotech biosimilars in Philippines
The biosimilars planned under this agreement include biosimilar Prolia (denosumab 60mg/ml) and Xgeva (denosumab 70 mg/ml) for treating osteoporosis, Simponi (golimumab) for treating rheumatoid arthritis, and Eylea (aflibercept) against wet-age macular degeneration as well as two undisclosed proposed biosimilars for immunology and oncology. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 7, 2022 Category: Pharmaceuticals Source Type: news
Efficacy and Safety of Arylia vs Prolia in Osteoporosis Efficacy and Safety of Arylia vs Prolia in Osteoporosis
Is this newly developed denosumab biosimilar as safe and effective as the reference product in the treatment of osteoporosis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 9, 2022 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Half the Denosumab Dose Still Maintains Bone Density Half the Denosumab Dose Still Maintains Bone Density
Postmenopausal women with osteoporosis who reached their bone mineral density target on standard denosumab (Prolia, Xgeva) therapy maintained the benefit when they switched to a half-dose regimen.First Look (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 20, 2022 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news
Treating Bone Loss Ups Survival for Patients With Breast Cancer Treating Bone Loss Ups Survival for Patients With Breast Cancer
Long-term data from a trial of adjuvant denosumab in patients with breast cancer suggest a survival benefit in addition to reduced fractures and increased bone density.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Denosumab Boosts Bone Strength in Glucocorticoid Users Denosumab Boosts Bone Strength in Glucocorticoid Users
Compared with risedronate, denosumab promoted bone strength in patients initiating glucocorticoids and those on long-term therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 12, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Oncology Care Model Reduces Cost of Supportive Care Meds Oncology Care Model Reduces Cost of Supportive Care Meds
The Oncology Care Model led to notable reductions in the use of the pricy monoclonal antibody denosumab, more rapid adoption of the biosimilar filgrastim, and more selective use of costly antiemetics.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia(R) and Xgeva(R)
BUDAPEST, Hungary and LONDON, Dec. 9, 2021 -- (Healthcare Sales & Marketing Network) -- Gedeon Richter Plc. ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement ... Biopharmaceuticals, Generics, Licensing Hikma Pharmaceuticals, Gedeon Richter, denosumab, Prolia , Xgeva (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 9, 2021 Category: Pharmaceuticals Source Type: news
Bone Gains Lost Following Denosumab Stop in Steroid-Treated RA Bone Gains Lost Following Denosumab Stop in Steroid-Treated RA
When denosumab is discontinued, glucocorticoid-treated patients with rheumatoid arthritis need to transition to another osteoporosis therapy.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - September 28, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news
Denosumab Now Dominant Therapy for Cancer-Associated Osteoporosis Denosumab Now Dominant Therapy for Cancer-Associated Osteoporosis
In changing patterns of osteoporosis drug prescriptions, denosumab has risen to the top of cancer indications.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 26, 2021 Category: Cancer & Oncology Tags: Diabetes & Endocrinology News Source Type: news
Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss
Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab versus oral alendronate, a small clinical trial shows.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - March 10, 2021 Category: Orthopaedics Tags: Rheumatology News Source Type: news
Denosumab Promising for Osteolysis After Total Hip Replacement Denosumab Promising for Osteolysis After Total Hip Replacement
Denosumab showed biological efficacy against osteolysis after total hip replacement in a proof-of-concept trial.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 21, 2021 Category: Orthopaedics Tags: Orthopaedics News Source Type: news
Denosumab Studied for Prosthesis-Related Osteolysis
THURSDAY, Jan. 21, 2021 -- For patients with symptomatic, radiographically confirmed osteolysis undergoing revision total hip arthroplasty surgery, a single dose of denosumab results in a reduction in osteoclast numbers, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2021 Category: Pharmaceuticals Source Type: news
Could an Osteoporosis Drug Reduce Need for Hip Revision Surgery? Could an Osteoporosis Drug Reduce Need for Hip Revision Surgery?
Denosumab, widely used to treat osteoporosis, may reduce the need for revision surgery due to aseptic loosening of the prosthesis in patients with osteolysis following a hip replacement.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Could an Osteoporosis Drug Reduce Need for Hip Revision Surgery? Could an Osteoporosis Drug Reduce Need for Hip Revision Surgery?
Denosumab, widely used to treat osteoporosis, may reduce the need for revision surgery due to aseptic loosening of the prosthesis in patients with osteolysis following a hip replacement.Medscape Medical News (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 14, 2021 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news
Denosumab Favored Over Alendronate for BMD Protection Denosumab Favored Over Alendronate for BMD Protection
"Glucocorticoids remain the mainstay of treatment of rheumatic diseases, but [they are] a major risk factor for osteoporosis and fracture."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news
